KULSOOM JUNAID: Open Payments
NPI 1497827968 · SAINT LOUIS, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,601 in 59 payments from 9 companies in 2025. Trend: 2023 $1,003 · 2024 $919 · 2025 $2,601
Food & beverage: $1,419Travel & lodging: $1,182
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 13 | $1,655 |
| Teva Pharmaceuticals USA, Inc. | 17 | $240 |
| E.R. Squibb & Sons, L.L.C. | 7 | $190 |
| Otsuka America Pharmaceutical, Inc. | 6 | $188 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 6 | $119 |
| Alkermes, Inc. | 5 | $102 |
| Vanda Pharmaceuticals Inc. | 2 | $52 |
| ACADIA Pharmaceuticals Inc | 2 | $37 |
| Janssen Pharmaceuticals, Inc | 1 | $19 |
Products named: COBENFY, INGREZZA, UZEDY, REXULTI, CAPLYTA, AUSTEDO XR, ARISTADA, ABILIFY MAINTENA.
Industry payments across MO — which companies pay providers there.
